Rhinomed (ASX:RNO) - CEO Michael Johnson
CEO Michael Johnson
Source: Rhinomed
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Rhinomed (RNO) receives a purchase order from the NSW Government for its COVID-19 testing nasal swab, Rhinoswab
  • NSW Health Pathology has ordered one million Rhinoswabs as part of its program to support testing capability
  • The company has started delivering and is expected the whole order to be completed over the coming weeks
  • On the market, Rhinomed is up 52.5 per cent, trading at 30.5 cents per share at 12:27 pm AEST

Rhinomed (RNO) has received a purchase order from the NSW Government for its COVID-19 testing nasal swab, Rhinoswab.

NSW Health Pathology has ordered one million Rhinoswabs as part of its program to support testing capability.

The company has started delivering and is expected the whole order to be completed over the coming weeks.

RNO is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this innovative technology.

The Rhinoswab technology improves the sample collection process, and is substantially more comfortable and easier to use than the standard nasal swab.

Importantly, the technology can speed up the sample collection process and significantly reduce queues and waiting times.

CEO Michael Johnson is thrilled with the order.

“The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easil,” Mr Johnson said.

“With approximately two billion SARS-CoV-2 tests having been carried out globally over the past 18 months (close to 26 million* in Australia alone), there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience.”

On the market, Rhinomed is up 52.5 per cent, trading at 30.5 cents per share at 12:27 pm AEST.

RNO by the numbers
More From The Market Herald
The Market Herald Video

" Antisense Therapeutics (ASX:ANP) shares rise on long COVID-19 study

Antisense Therapeutics (ASX:ANP) announces the initial outcomes of its collaboration to study the neurological aspects of…
The Market Herald Video

" Immuron (ASX:IMC) shifts focus to therapeutic drug candidate

Immuron (ASX:IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug…
The Market Herald Video

" Bod Australia (ASX:BOD) awarded US Hemp Authority certificate for CBD extract

Bod Australia (ASX:BOD) has been awarded US Hemp Authority Certification for its exclusive CBD extract and…
The Market Herald Video

" Fisher & Paykel (ASX:FPH) flags softer profits for first half of FY23

Fisher & Paykel Healthcare (ASX:FPH) has forecast weaker revenue and profits for the half-year to the…